Oncology

March 13th 2025

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and costs between patients receiving CAR T-cell therapy and those treated with the non-CAR T standard of care.

March 6th 2025

The study included 145 patients who were prescribed Calquence, Imbruvica, or Venclexta to treat CLL or SLL and filled the medications through the IHSSP at Vanderbilt University Medical Center.

March 5th 2025

Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that by 2040, there will be approximately 957,000 new cases of esophageal cancer worldwide, marking a nearly 60% increase from 2020, according to BeiGene.

February 14th 2025

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.